AlphAIAlphAI — Financial news for AI agents
prnewswire.comOCT 13 min read$NKTR

New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026

Nektar Therapeutics (NKTR) presented long-term data on rezpegaldesleukin at EADV 2026, showing durable hair regrowth in alopecia areata patients and sustained improvements in atopic dermatitis. Key findings include 75% maintaining SALT Score ≤20 after 4 months off-treatment and 19% achieving SALT Score ≤10 after 6 months. Phase 3 studies are planned for both indications, with ZENITH AA to start in early 2027. The company will host an investor call on Oct. 1, 2026.

Original reporting
prnewswire.com
Published Oct 1, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 11:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 — source image
Source · prnewswire.com
Decision brief

The 30-second read

$NKTRBullishMed
01

Why it matters

The data provide the first evidence of sustained hair regrowth and skin improvement after treatment cessation, supporting advancement to Phase 3 trials.

02

Market read

Positive trial data could drive NKTR stock higher ahead of Phase 3 initiation, with modest spillover to the broader biotech sector.

03

What to watch

Potential regulatory hurdles and competition from other biologics in the same indications.

Relevance 8/10Novelty 8/10Timing: today

Background

Nektar Therapeutics (NASDAQ: NKTR) announced long‑term Phase 2b data for rezpegaldesleukin at the EADV Congress, covering both alopecia areata and atopic dermatitis.

Company-level read

Ticker impact

$NKTRBullishHigh confidence
Context

Nektar Therapeutics presented new Phase 2b data showing durable efficacy of rezpegaldesleukin in alopecia areata and atopic dermatitis.

Expected impact

likely upside as investors price in the durable efficacy and upcoming Phase 3 trials

Evidence & confidence

The data are first‑time disclosures of long‑term durability and deepening response, a material catalyst for a biotech with an upcoming pivotal program.

Market effects

Sector

Strengthens the Treg‑targeted immunology segment and may boost peer biotech valuations.

Regional

U.S. biotech sector could see modest gains on the back of the data.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

If Phase 3 fails to replicate durability, the hype could reverse sharply.

Key entities

  • Company
    Nektar Therapeutics

    Biopharma developing rezpegaldesleukin, listed on NASDAQ.

  • Drug
    Rezpegaldesleukin

    Novel regulatory T‑cell agonist being tested in dermatologic indications.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 1
$NKTRMedAI 9/10

Nektar presents durable Phase 2b rezpegaldesleukin data; Phase 3 ZENITH AA starts early 2027

Nektar reported positive Phase 2b results for rezpegaldesleukin in alopecia areata and atopic dermatitis, showing durable responses. 31% of patients achieved SALT ≤20 after 52 weeks, with 63% maintaining it 6 months off treatment. Phase 3 trials, ZENITH AA and ZENITH AD, are planned to start in early 2027. According to the company, the data supports the drug's potential.

tradingview.com2 min
OCT 1
$NKTRHighAI 8/10

NEKTAR THERAPEUTICS (NKTR): New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026

NEKTAR THERAPEUTICS (NKTR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 Rezpegaldesleukin demonstrated durability and deepening of response through one year of treatment in two de

SEC EDGAR 8-K2 min
OCT 1
$NKTRMedAI 8/10

Nektar presents long-term data on alopecia areata drug candidate

Nektar Therapeutics (NKTR) presented long-term data on rezpegaldesleukin for alopecia areata and atopic dermatitis at a dermatology congress. In a Phase 2b study, 75% of alopecia patients maintained hair coverage 4 months post-treatment. The company plans Phase 3 trials for both conditions. Rezpegaldesleukin has FDA Fast Track designation for both indications.

investing.com2 min
SEP 30
$NKTRMedAI 8/10

Nektar Advances Rezpegaldesleukin In Atopic Dermatitis With Early Biomarker Data

Nektar Therapeutics (NKTR) reported Phase 2b data showing rezpegaldesleukin produced early molecular changes in patients with moderate-to-severe atopic dermatitis. The biologic increased Treg-associated markers and modulated multiple immune pathways, with significant biomarker changes correlating with clinical improvements. NKTR plans to advance the candidate to Phase 3, which has FDA Fast Track designation. NKTR stock is currently at $61.00, up 2.97%.

rttnews.com2 min